News

📅 [SAVE THE DATE] 28 June - 1 July 2022 📣 Come and meet our experts at the PAGE Meeting in Ljubljana, Slovenia - to discuss the latest in pharmacometrics and population PK & PD modeling.

PhinC is conducting a research project to develop and validate innovative modeling methodologies applied to the specific development of monoclonal antibodies (mAbs).

Read the interview of our President Bernard Orlandini, along with Marc Essodaigui, CEO of Active Biomarkers and Alexandre Durand-Salmon, CEO of Banook Group.

Translational PK/PD and Model-Informed Drug Development (MIDD) of monoclonal antibodies

We are officially a member of the "La French Tech Paris-Saclay" community. An association that federates, creates connections and offers opportunities.

The independent medical publication Prescrire.org rewards Fexinidazole

Consider current and future data regulations when planning studies for your development program.

In vitro-In vivo is a strategic tool in drug developement, discover why!

Population Pharmacokinetics (PopPK), a crucial approach in drug development